(64)Cu-SAR-Bombesin PET-CT Imaging in the Staging of Estrogen/Progesterone Receptor Positive, HER2 Negative Metastatic Breast Cancer Patients: Safety, Dosimetry and Feasibility in a Phase I Trial

Breast cancers are most frequently oestrogen receptor (ER) and progesterone receptor (PR) positive and [(18)F]Fluorodeoxyglucose PET-CT (FDG) has lower sensitivity for these subtypes. The gastrin-releasing peptide receptor (GRPR) is overexpressed in ER+/PR+ breast cancers. This study assessed the sa...

Descripción completa

Detalles Bibliográficos
Autores principales: Wong, Keith, Sheehan-Dare, Gemma, Nguyen, Andrew, Ho, Bao, Liu, Victor, Lee, Jonathan, Brown, Lauren, Dear, Rachel, Chan, Lyn, Sharma, Shikha, Malaroda, Alessandra, Smith, Isabelle, Lim, Elgene, Emmett, Louise
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9316435/
https://www.ncbi.nlm.nih.gov/pubmed/35890071
http://dx.doi.org/10.3390/ph15070772

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9316435/
https://www.ncbi.nlm.nih.gov/pubmed/35890071
http://dx.doi.org/10.3390/ph15070772

Ejemplares similares